ALIMERA SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.56 USD | +0.54% |
|
+76.51% | +28.70% |
| 25/06 | Maxim Downgrades Alimera Sciences to Hold From Buy | MT |
| 25/06 | Alliance Global Partners Downgrades Alimera Sciences to Neutral From Buy, Adjusts Price Target to $5.50 From $8 | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +28.70% | 29Cr | - | ||
| +2.99% | 9.48TCr | A- | ||
| -4.34% | 3.76TCr | A- | ||
| -10.41% | 3.33TCr | B- | ||
| +75.79% | 2.79TCr | A | ||
| -14.61% | 1.59TCr | C | ||
| -3.46% | 1.38TCr | B- | ||
| -12.31% | 1.15TCr | D+ | ||
| +184.77% | 1.09TCr | D | ||
| -54.13% | 927.07Cr | B |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ALIM Stock
- Ratings Alimera Sciences, Inc.
